SPOT

SPOT is a novel Clinician Decision Support Digital Health CE-marked medical device platform. Using AI, SPOT is able to harness information to enable the development of guidelines and predict prescriber performance to ensure safe and effective treatment of pain. SPOT supports prescribers switching patients addicted or misusing opioids to buprenorphine as part of a medication-assisted treatment regime to reduce the risk of opioid overdose death. SPOT is also used in palliative and end of life care settings to support opioid switch in cases of toxicity or unwanted side effects. In a real world, cross setting and multi-professional study in the NHS it is proven to significantly improve the confidence of opioid prescribing in users and adherence to best practice guidelines. SPOT is designed to reduce unwarranted variation and primary and secondary harms when prescribing opioids whilst supporting warranted variation of choice to align to individual situations, values and side effect profiles. SPOT is able to monitor drug usage and spend and suggest lower-cost opioids to users to reduce costs to healthcare organisations. SPOT is currently in use in the NHS.